scispace - formally typeset
W

Wickerham Dl

Researcher at University of Pittsburgh

Publications -  9
Citations -  8227

Wickerham Dl is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 9, co-authored 9 publications receiving 8018 citations.

Papers
More filters
Journal ArticleDOI

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.

TL;DR: Preoperative therapy reduced the size of most breast tumors and decreased the incidence of positive nodes in women with primary breast cancer and should be considered for the initial management of breast tumors judged too large for lumpectomy.
Journal ArticleDOI

A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive Tumors

TL;DR: Tamoxifen significantly reduced the rate of treatment failure at local and distant sites, tumors in the opposite breast, and the incidence of tumor recurrence after lumpectomy and breast irradiation and was attained with a low incidence of clinically appreciable toxic effects.
Journal ArticleDOI

Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer.

TL;DR: The findings continue to indicate that lumpectomy followed by breast irradiation is appropriate therapy for women with either negative or positive axillary nodes and breast tumors 4 cm or less in diameter.
Journal ArticleDOI

Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation

TL;DR: It is indicated that the location of a breast tumor does not influence the prognosis and that irradiation of internal mammary nodes in patients with inner-quadrant lesions does not improve survival and that the results obtained at five years accurately predict the outcome at 10 years.
Journal ArticleDOI

Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14

TL;DR: Risk of endometrial cancer increases following tamoxifen therapy for invasive breast cancer; however, net benefit greatly outweighs risk, and tamoxIFen treatment for breast cancer should continue.